These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6159502)

  • 1. Adjunctive management of thyroid cancer: chemotherapy.
    Shimaoka K
    J Surg Oncol; 1980; 15(3):283-6. PubMed ID: 6159502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy for anaplastic carcinoma of the thyroid.
    Sokal M; Harmer CL
    Clin Oncol; 1978 Mar; 4(1):3-10. PubMed ID: 76520
    [No Abstract]   [Full Text] [Related]  

  • 3. Preoperative chemotherapy for giant cell carcinoma of the thyroid.
    Spanos GA; WolK D; Desner MR; Khan A; Platt N; Khafif RA; Cortes EP
    Cancer; 1982 Dec; 50(11):2252-6. PubMed ID: 6182970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug therapy of thyroid malignomas (author's transl)].
    Reinwein D
    Strahlentherapie; 1978 Jun; 154(6):365-7. PubMed ID: 78550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combined doxorubicin and bleomycin treatment of metastasising thyroid carcinoma: results in 21 patients (author's transl)].
    Benker G; Hackenberg K; Hoff HG; Seeber S; Ebke J; Windeck R; Reinwein D
    Dtsch Med Wochenschr; 1977 Dec; 102(52):1908-13. PubMed ID: 74313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
    Wang W; Zhou J; Zhao L; Chen S
    Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemotherapy of thyroid carcinoma (author's transl)].
    Brunner K
    Schweiz Rundsch Med Prax; 1982 Apr; 71(14):603-5. PubMed ID: 7201137
    [No Abstract]   [Full Text] [Related]  

  • 8. A partial response in anaplastic carcinoma of the thyroid with liposomal doxorubicin.
    Moscetti L; Padalino D; Capomolla E; Nelli F; Pollera CF
    J Exp Clin Cancer Res; 2005 Mar; 24(1):151-4. PubMed ID: 15943045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of the patient with progressive radioiodine non-responsive disease.
    Haugen BR
    Semin Surg Oncol; 1999; 16(1):34-41. PubMed ID: 9890738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
    Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion of non-iodine-concentrating differentiated thyroid carcinoma metastases into iodine-concentrating foci after anticancer chemotherapy.
    Morris JC; Kim CK; Padilla ML; Mechanick JI
    Thyroid; 1997 Feb; 7(1):63-6. PubMed ID: 9086573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy and multimodality treatment in thyroid carcinoma.
    Ekman ET; Lundell G; Tennvall J; Wallin G
    Otolaryngol Clin North Am; 1990 Jun; 23(3):523-7. PubMed ID: 1694985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium.
    Matuszczyk A; Petersenn S; Bockisch A; Gorges R; Sheu SY; Veit P; Mann K
    Horm Metab Res; 2008 Mar; 40(3):210-3. PubMed ID: 18348081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
    Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy of metastatic thyroid cancer. Phase II study.
    Bukowski RM; Brown L; Weick JK; Groppe CW; Purvis J
    Am J Clin Oncol; 1983 Oct; 6(5):579-81. PubMed ID: 6193705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
    Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
    Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of chemotherapy in thyroid cancer].
    Benker G; Reinwein D
    Dtsch Med Wochenschr; 1983 Mar; 108(11):403-6. PubMed ID: 6186447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy in radioiodine refractory thyroid cancer.
    Pacini F; Brilli L; Marchisotta S
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):520-5. PubMed ID: 19910905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medullary thyroid cancer treated by capecitabine.
    Labidi SI; Gravis G; Tarpin C; Brun V; Viens P
    Anticancer Drugs; 2007 Aug; 18(7):831-4. PubMed ID: 17581307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.